6-cyclopropyl-3-[2-(3-methoxyphenyl)-2-oxoethyl]-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione | 1084623-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-cyclopropyl-3-[2-(3-methoxyphenyl)-2-oxoethyl]-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
• 英文别名: 6-cyclopropyl-3-[2-(3-methoxyphenyl)-2-oxoethyl]-1-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]thieno[2,3-d]pyrimidine-2,4-dione
• CAS: 1084623-00-6
• 化学式: C₃₃H₂₆N₄O₆S
• 分子量: 606.659
• InChiKey: NFMSULBFOWOXHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  44
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  146
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-cyclopropyl-3-[2-(3-methoxyphenyl)-2-oxoethyl]-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione 在 potassium 2-ethylhexanoate 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 16.0h， 以93%的产率得到6-cyclopropyl-3-[2-(3-methoxyphenyl)-2-oxoethyl]-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione potassium salt
  参考文献：
  名称：

  EP2151440

  摘要：

  公开号：
• 作为产物：
  描述：

  、 N,N'-羰基二咪唑 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 6-cyclopropyl-3-[2-(3-methoxyphenyl)-2-oxoethyl]-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  EP2151440

  摘要：

  公开号：

文献信息

• HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：Kuroita Takanobu

  公开号：US20100137281A1

  公开（公告）日：2010-06-03

  The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like, which is useful for the prophylaxis or treatment s of circulatory diseases such as hypertension, cardiac diseases, arteriosclerosis, renal diseases, cerebral apoplexy and the like and/or metabolic diseases such as hyperlipidemia, obesity, diabetes and the like, central nervous disorders such as cerebral infarction and the like, mental diseases such as dementia, depression and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明旨在提供一种具有优异的药理作用、物理化学性质等的化合物，该化合物对预防或治疗循环系统疾病，如高血压、心脏疾病、动脉硬化、肾脏疾病、脑卒中等，和/或代谢性疾病，如高脂血症、肥胖、糖尿病等，中枢神经系统疾病，如脑梗死等，精神疾病，如痴呆、抑郁症等，等方面具有用途。该化合物由式（I）所表示，其中每个符号如规范中所定义，或其盐。
• Heterocyclic compound and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2253630A1

  公开（公告）日：2010-11-24

  The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like, which is useful for the prophylaxis or treatment of circulatory diseases such as hypertension, cardiac diseases, arteriosclerosis, renal diseases, cerebral apoplexy and the like and/or metabolic diseases such as hyperlipidemia, obesity, diabetes and the like, central nervous disorders such as cerebral infarction and the like, mental diseases such as dementia, depression and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明旨在提供一种具有优异药理作用、理化性质等的化合物，该化合物可用于预防或治疗循环系统疾病，如高血压、心脏病、动脉硬化、肾病、脑中风等，和/或代谢性疾病，如高脂血症、肥胖症、糖尿病等，中枢神经疾病，如脑梗塞等，精神疾病，如痴呆症、抑郁症等。 由式（I）代表的化合物： 其中各符号如说明书中所定义，或其盐。
• US8501750B2
  申请人：——

  公开号：US8501750B2

  公开（公告）日：2013-08-06